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Burden of Disease
Internationally, lung cancer continues to be the leading 
cause of cancer-related deaths in men and women [1]. A 
breakdown by level of economic development shows no 
differences in cancer deaths in men but a higher rate of 
lung cancer deaths in women in industrialized countries 
as compared with developing nations. Among females 
in developing countries, lung cancer deaths lag behind 
those due to breast cancer [2]. Lung cancer incidence and 
mortality are tightly linked to cigarette smoking patterns. 
As smoking rates peak – generally first in men, followed 
by women – lung cancer incidence and mortality rise in 
subsequent decades before declining following the initia-
tion of comprehensive tobacco control programs [3–5]. 
These trends have occurred earlier in industrialized 
countries as compared with the developing world. In the 
United States (US) and the United Kingdom (UK), lung 
cancer incidence and mortality rates have in fact been 
falling since the 1990s. In contrast, emerging nations – 
including Brazil, Russia, India, China, and South Africa 
(BRICS) – continue to have high rates of cigarette smok-
ing in both men and women. They exhibit a lower inci-
dence of cancer but a higher mortality burden compared 
with developed countries. Reasons for these patterns 
include unequal access to healthcare leading to delayed 
diagnosis and treatment, environmental contamination, 
and sociocultural barriers [6].
Industrialized Countries
In the US, the incidence of lung cancer in men peaked in 
the 1980s, followed by a subsequent decline, with similar 
patterns in women following 20 years later [7]. Thun et 
al. found that in the 1960s, the relative risk of lung can-
cer death in smokers versus non-smokers was more than 
four times higher in men than in women. In the 40 years 
since, women’s risk has risen markedly, becoming nearly 
identical to that of men [3, 8]. Lung cancer deaths in men 
are now declining at an average of 2.9% annually with a 
percent decrease roughly double that of women [7]. With 
regard to differences between racial and ethnic groups, 
non-Hispanic whites and blacks have the highest inci-
dence and death rates [9]. In particular, black men have 
the highest mortality, approximately double that of Asian 
Americans, the group with the lowest cancer-specific mor-
tality [7, 10]. These racial and ethnic disparities are largely 
due to differences in cigarette smoking prevalence, as 
well as lower rates of resection and higher probability of 
advanced stage at diagnosis in minorities [11–13].
The UK has similar smoking and lung cancer incidence 
trends to the US. Male smoking prevalence peaked in the 
1940s to 1950s, followed by a peak in lung cancer inci-
dence in the 1970s. Despite declining rates in both sexes, 
lung cancer remains the second most common malig-
nancy in the UK [14]. Mainland Europe exhibits wide 
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REVIEW
Global Epidemiology of Lung Cancer
Julie A. Barta*, Charles A. Powell† and Juan P. Wisnivesky†,‡
While lung cancer has been the leading cause of cancer-related deaths for many years in the United 
States, incidence and mortality statistics – among other measures – vary widely worldwide. The aim of 
this study was to review the evidence on lung cancer epidemiology, including data of international scope 
with comparisons of economically, socially, and biologically different patient groups. In industrialized 
nations, evolving social and cultural smoking patterns have led to rising or plateauing rates of lung cancer 
in women, lagging the long-declining smoking and cancer incidence rates in men. In contrast, emerging 
economies vary widely in smoking practices and cancer incidence but commonly also harbor risks from 
environmental exposures, particularly widespread air pollution. Recent research has also revealed clinical, 
radiologic, and pathologic correlates, leading to greater knowledge in molecular profiling and targeted 
therapeutics, as well as an emphasis on the rising incidence of adenocarcinoma histology. Furthermore, 
emergent evidence about the benefits of lung cancer screening has led to efforts to identify high-risk 
smokers and development of prediction tools. This review also includes a discussion on the epidemiologic 
characteristics of special groups including women and nonsmokers. Varying trends in smoking largely 
dictate international patterns in lung cancer incidence and mortality. With declining smoking rates in 
developed countries and knowledge gains made through molecular profiling of tumors, the emergence of 
new risk factors and disease features will lead to changes in the landscape of lung cancer epidemiology.
Barta et al: Global Epidemiology of Lung CancerArt. 8, page 2 of 16 
geographic variations in lung cancer incidence (Figure 1). 
In general, rates are highest in central and eastern Europe, 
but incidence throughout the continent has been declin-
ing in men since the early 1990s. Exceptions include 
Norway, Finland, Spain, and France, where lung cancer 
rates have remained stable. In women, rising lung cancer 
incidence has slowed in the US and UK, but rates continue 
to increase in central and eastern Europe [15–20]. These 
regional differences reflect earlier stages of the tobacco 
epidemic in countries such as Belarus, Hungary, Poland, 
and the Russian Federation [4, 5, 15, 17]. Additionally, 
socioeconomic and educational inequalities, as well as 
diagnosis at later stages of disease, contribute to variabil-
ity in lung cancer incidence and mortality within Europe 
[21, 22]. Finally, similarly to the US, lung cancer survival 
is lower than that of any other common malignancies in 
Europe. EUROCARE-5 reported a mean five-year survival 
of 13% for all lung cancer patients diagnosed in 2000–
2007, with a range from 9% in the UK and Ireland to 15% 
in central Europe [23, 24]. 
In Asia, Japan has high incidence and mortality rates 
from lung cancer, comparable to those of the US and 
Europe [25]. Men have had a higher incidence of lung 
cancer than women since the 1970s and continue to com-
prise the majority of new lung cancer cases in Japan today, 
largely due to gender differences in smoking prevalence 
[26]. Conversely, mortality rates in women are lower in 
Japan than in other industrialized nations, perhaps due to 
the higher incidence of adenocarcinomas with mutations 
responsive to targeted therapies [27]. 
Emerging Economies
Brazil, Russia, India, China, and South Africa are recog-
nized by their large and fast-growing economies [28]. One 
of the few South American countries with a cancer regis-
try is Brazil, where tobacco smoking peaked in the 1970s 
and lung cancer mortality in men peaked in 1993 and 
continues to rise among women [29, 30]. Likewise, in the 
Russian Federation, all-cause mortality in men is largely 
attributed to very high rates (60%) of both smoking and 
alcohol consumption, which are much lower in women 
[6]. Accordingly, Russia has among the highest lung can-
cer mortality rate in men of all European countries but 
among the lowest in women. Mortality is now declining, 
after peaking in the early 1990s, but tobacco use remains 
a major barrier to effective cancer control [16]. Additional 
risk factors in Russia include environmental pollution and 
workplace exposures in nuclear facilities and asbestos 
mines [6].
Comparatively, lung cancer incidence and mortality rates 
in India are among the lowest in the world [4]. The most 
common cancers in men are head and neck, gastric, and 
Figure 1: Global lung cancer incidence and mortality. Global age-standardized incidence and mortality rates for lung 
cancer, 20 countries with the highest rates internationally. Reproduced from GLOBOCAN 2012 data with permission.
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esophageal cancers, attributed to high usage of smoke-
less tobacco; the most common cancers among women 
are cervical and breast. One study in northern India noted 
that squamous cell lung cancer was the most common 
histology overall and among smokers [31]. While cigarette 
smoking has a reported prevalence ranging from 28 to 
57% among men, bidi smoking (hand-rolled tobacco) is 
the most commonly used (92%) tobacco product [32].
In 2005, the total number of new lung cancer cases in 
China was over 500,000. According to GLOBOCAN 2012, 
lung cancer is the most common malignancy and cause 
of cancer mortality in China, representing 21% of all can-
cers and 27% of all cancer-related deaths [6]. Lung can-
cer incidence and mortality is higher in eastern China 
and in urban areas, which has been attributed to west-
ernization of lifestyle [33]. However, mortality rates are 
increasing faster in rural areas due to poor access to care 
[6]. Additionally, age-adjusted mortality rates are higher 
in Chinese men – 68% of whom are smokers – but lung 
cancer incidence rates are rising faster in women [34]. Risk 
factors among Chinese women include secondhand smok-
ing, air pollution, and domestic use of biomass fuels [35].
Developing Countries
Reporting of cancer epidemiology in Africa is limited by 
the lack of reliable registries. Among countries on the 
African continent as whole, both incidence and mortal-
ity rates are low – lung cancer was the fifth most com-
mon site of cancer in African men and not even in the top 
10 for women. This is likely due to the low prevalence of 
smoking (10% in men and <2% in women) as well as the 
lower life expectancy of the population. Lung cancer does 
have a high incidence in certain regions including the 
northern African countries of Western Sahara, Morocco, 
Algeria, Tunisia, and Libya, and it is the leading cause of 
cancer death in men in northern and southern Africa [36]. 
South America has a wide range of lung cancer inci-
dence across countries and markedly higher rates in men 
compared with women. The highest incidence and mor-
tality in men can be found in Uruguay and in women of 
Venezuela and Argentina. Less populated countries such 
as Ecuador, Bolivia, and Guyana have very low age-stand-
ardized rates, just higher than those of central Africa and 
the Middle East [25]. 
The remainder of Asia has extremely diverse lung cancer 
incidences, which are nevertheless consistent within dif-
ferent regions. Asian countries closest to Eastern Europe 
such as Armenia, Turkey, and Kazakhstan have among the 
highest rates of lung cancer in the world. Korea and south-
east Asia have slightly lower rates, and Middle Eastern 
countries including Yemen and Saudi Arabia have among 
the lowest lung cancer incidence rates in the world [25]. 
These notable regional differences reflect geographic 
trends in the tobacco epidemic [37].
Histopathology
Lung cancer was traditionally classified into two primary 
groups, small versus non–small cell type. This grouping 
was progressively specified with the use of histopatho-
logic features and immunohistochemical markers, and 
now inroads are being made in distinguishing invasive 
adenocarcinomas from pre-invasive lesions. Moreover, 
further knowledge about the molecular characteristics 
of lung cancers and the availability of targeted thera-
pies has substantially impacted the classification of lung 
cancers.
Histology
Adenocarcinoma is the most common histologic sub-
type of lung cancer in men and women [38]. Prior to the 
1990s, squamous cell lung carcinoma was the most com-
mon histologic subtype, particularly among men. Since 
then, the incidence of adenocarcinoma rose to be greater 
than that of squamous cell carcinomas in the US, Canada, 
many European countries, and Japan [26, 39]. However, 
this switch has not yet been observed in other countries 
such as Spain and the Netherlands [39]. The higher rates 
of adenocarcinoma relative to squamous and small cell 
lung cancer are greater in women [4]. Consequently, the 
proportion of adenocarcinomas is rising in many coun-
tries in parallel to increased incidence of lung cancer in 
women. These findings may reflect differences in the 
types of cigarettes (including filtered and low-tar ver-
sions) more frequently used by women as well as genetic 
predisposition and environmental exposures in female 
never-smokers [39].
In 2011, the International Association for the Study of 
Lung Cancer, American Thoracic Society, and European 
Respiratory Society proposed a new adenocarcinoma cat-
egorization based upon histological evidence of invasion. 
Preinvasive lesions are classified on a continuum from 
atypical adenomatous hyperplasia (AAH) to adenocar-
cinoma in situ (AIS), and minimally invasive adenocarci-
noma (MIA) includes small (<3 cm) lesions with ≤5 mm 
of invasion. Invasive adenocarcinomas include a variety 
of patterns (e.g., lepidic predominant adenocarcinoma 
[LPA], acinar, papillary, micropapillary, and solid) char-
acterized by tumor disruption of >5 mm of the alveolar 
basement membrane. This grouping correlates with clini-
cal outcomes, with pre-invasive lesions having an indolent 
clinical course with almost 100% curability, in contrast 
to invasive carcinomas, which have a considerably worse 
prognosis [40]. Recent studies have shown AIS, MIA, and 
LPA to have a higher incidence in Japan compared with 
western populations [27].
Squamous cell lung cancer is the second most common 
subtype, comprising approximately 20% of primary lung 
neoplasms in the US. These tumors are distinguished his-
tologically by squamous pearl formation, keratin produc-
tion, and intercellular bridging. Historically, squamous 
cell lung cancer occurred more commonly as central 
lesions, but peripheral tumors are rising in incidence [41]. 
Small cell lung cancer, which has an aggressive clinical 
course, comprises 14% of lung cancers and typically pre-
sents as a perihilar mass with early and extensive lymph 
node metastases. It has a strong association with smoking 
history and commonly causes paraneoplastic syndromes. 
Less frequent histologic subtypes of lung cancer include 
large cell (3%), adenosquamous (1–2%), and carcinoid 
tumors (1–2%) [41].
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Molecular Markers 
The most common genetic alterations in lung adenocar-
cinoma are epidermal growth factor receptor (EGFR) and 
KRAS activating mutations (Figure 2). EGFR insertions 
and deletions are found in roughly 15% of lung adeno-
carcinomas in the US, with increased frequency in non-
smokers (43% vs. 11% in smokers) [42] and Asians (up to 
60% in Asian women) [43]. In advanced stages of disease, 
this mutation predicts a more favorable prognosis and 
sensitivity to EGFR tyrosine kinase inhibitors (TKIs) such 
as erlotinib, gefitinib, and afatinib [44]. Conversely, KRAS 
mutations occur more commonly in smokers and appear 
to confer worse prognosis [42]. While no targeted thera-
peutics are currently available for this mutation, clinical 
trials are in progress to test drugs that target downstream 
effectors of activated KRAS [44]. Additional driver muta-
tions in lung adenocarcinoma occur with a frequency of 
<1–4%, including ALK gene rearrangements, ROS1 trans-
locations, HER2 mutations, BRAF mutations, and RET 
translocations. ALK rearrangement are clinically impor-
tant however, as this mutation creates a fusion product, 
most frequently with EML4, which predicts sensitivity to 
ALK tyrosine kinase inhibitors such as crizotinib and ceri-
tinib [44]. Additionally, ALK-positive tumors have been 
associated with acinar or solid histological patterns with 
signet ring features [45, 46].
Risk Factors and Environmental Exposures
The myriad risk factors for lung cancer most commonly 
include lifestyle, environmental, and occupational expo-
sures. The roles these factors play vary depending on 
geographic location, sex and race characteristics, genetic 
predisposition, as well as their synergistic interactions. 
Cigarette Smoking, Secondhand Smoking, and 
E-cigarettes
Cigarette smoking is the most recognized risk factor for 
developing lung cancer. Since the Surgeon General’s 
report on smoking and health in 1964, at which time 
52% of American men and 35% of American women were 
active smokers, the prevalence of cigarette smoking in US 
and consequently lung cancer has markedly decreased 
[47]. While nicotine itself is not carcinogenic, there be 
as many as 55 substances in cigarette smoke that have 
been deemed carcinogenic by the International Agency 
for Research on Cancer including polycyclic aromatic 
hydrocarbons and 4-(methylnitrosamino)-1-(3-pyridyl)-1-
butanone (NNK). Their activation leads to the formation 
of DNA adducts and subsequent gene methylation, DNA 
sequence changes, DNA segment amplification or dele-
tion, or whole chromosome gains or losses [48]. Relative 
risk of lung cancer in smokers as compared with smok-
ers varies from 10- to 30-fold, and the degree of risk is 
dependent on number of cigarettes smoked daily and 
pack-years of smoking. Cigar and pipe tobacco smoking 
are also associated with increased odds of developing lung 
cancer [49].
Secondhand smoke exposure also leads to a dose-
dependent risk of lung cancer. Öberg and colleagues stud-
ied the effects of environmental tobacco exposure (ETS) 
in 192 countries on six continents and found that 40% 
of children and 33%–35% of non-smokers are exposed 
to secondhand smoke. The highest rates were in Europe, 
the western Pacific, and parts of Southeast Asia; the lowest 
rates were found in Africa. Over 600,000 deaths worldwide, 
most of them in women, were attributable to secondhand 
smoking in 2004 [50]. Similar to Öberg’s finding of the 
relative risk for lung cancer in adult non-smokers exposed 
to secondhand smoke of 1.21 (95% confidence interval 
[CI]: 1.13–1.3), many regulatory bodies have reported an 
increase in lung cancer risk by 20 to 30% upon exposure 
to ETS [51–55]. The largest numbers of estimated deaths 
in adults attributable to secondhand smoke, however, are 
not due to lung cancer but rather ischemic heart disease 
and asthma [50].
Electronic cigarettes have sparked much recent contro-
versy over potential risks from long-term use, as well as 
their role in smoking initiation and potentially cessation 
Figure 2: Frequencies of common driver mutations in lung adenocarcinoma in the US and Europe. By overall 
frequency (A) and population group (B). Data are derived from large clinicopathologic cohort studies published since 
2008 and are representative of US and European populations. 
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[56]. The 2012 National Youth Tobacco Survey found the 
prevalence of ever-use of e-cigarettes among middle and 
high school students in the US to be 6.8%, while preva-
lence among adults in the simultaneous National Adult 
Tobacco Survey was 1.9% [57, 58]. Although conventional 
cigarette use is far higher (18% among adults), the inci-
dence of e-cigarette use is rising rapidly and has been asso-
ciated with higher odds of cigarette smoking and lower 
odds of abstinence [59, 60]. Even more concerning, early 
research has shown that an e-cigarette vapor-conditioned 
media induced gene expression patterns in human bron-
chial epithelial cells concordant with that of cells exposed 
to a cigarette smoke-conditioned media [61].
Domestic Biomass Fuels 
Unprocessed biomass fuels, including wood, crop resi-
dues, dung, and coal, are used by approximately half of the 
world’s population for in-home cooking or heating, pri-
marily in eastern and southern Asia [62]. Indoor emissions 
in these households contain high concentrations of poly-
cyclic aromatic hydrocarbons, benzene, and other carcino-
genic compounds [63]. Several studies have confirmed an 
increased lung cancer risk associated with biomass fuels, 
with one pooled analysis showing an odds ratio (OR) of 
4.93 (95% CI: 3.73–6.52) among coal users in Asia when 
compared with nonsolid-fuel users [64, 65]. A meta-anal-
ysis including subjects from Europe and North America, 
in addition to Asia, reported similar trends in lung cancer 
risk with exposure to coal, biomass, and mixed fuels [62]. 
Additional studies have reported increased risk with bitu-
minous “smoky coal” use compared with anthracite-based 
“smokeless coal,” as well as higher risk with domestic expo-
sures in smokers compared with nonsmokers [63, 66].
COPD and other Pulmonary Conditions 
While epidemiological studies report that approximately 
20–30% of smokers develop COPD and 10–15% develop 
lung cancer, COPD is by far the most common comorbid-
ity in patients with lung cancer, with a varying prevalence 
between 30 and 70% [67]. A cohort of newly diagnosed 
lung cancer cases was reported to have a prevalence of 
COPD as high as six-fold greater than matched smokers 
without cancer [67]. Additional studies have shown factors 
such as increasing degree of airway obstruction, increasing 
age, lower body mass index, and a diffusing lung capacity 
of carbon monoxide < 80% to be associated with a diag-
nosis of lung cancer [68]. Furthermore, extent of emphy-
sema on CT is an independent risk factor for lung cancer, 
as well as a predictor of cancer-specific mortality [69, 70]. 
A recent pooled analysis of almost 25,000 cases from the 
International Lung Cancer Consortium also showed both 
lung cancer incidence and mortality to be significantly 
associated with emphysema [71, 72]. Proposed mecha-
nisms for the link between COPD and lung cancer include 
matrix remodeling and lung repair processes which lead 
to development of epithelial-mesenchymal transition and 
carcinogenesis. Additionally, several genome-wide asso-
ciation and candidate gene studies have identified asso-
ciations between emphysema and lung cancer at several 
chromosomal loci, supporting that susceptibility to lung 
cancer may include COPD-related gene variants [73]. In 
a large meta-analysis, never-smokers with a history of 
chronic bronchitis, tuberculosis, or pneumonia were 
found to have an increased risk of lung cancer [71, 74].
Occupational Exposures 
Exposure to asbestos is one of the most well-recognized 
occupational causes of lung cancer. Workers in asbestos 
mining and milling, shipbuilding, construction, textiles 
and insulation, and automobile repair are at the highest 
risk. Multiple mechanisms exist for carcinogenesis, includ-
ing induction of oxidative damage and subsequent DNA 
deletions, somatic gene alterations, and enhanced deliv-
ery of tobacco carcinogens to the airway epithelium [75]. 
Markowitz and colleagues evaluated 2,377 North Ameri-
can insulators and found increased lung cancer risk to be 
associated with asbestos exposure (rate ratio: 3.6, 95% CI: 
1.7–7.6) and asbestosis (rate ratio: 7.4, 95% CI: 4.0–13.7), 
with synergistic effects in smokers [76]. Diesel exhaust 
exposure has also been studied in trucking industry work-
ers and coal miners. The SYNERGY project, a pooled anal-
ysis of 11 case-control studies conducted in Europe and 
Canada, which included 13,304 cases, showed that cumu-
lative diesel exposure was associated with an increased 
lung cancer risk (OR: 1.31, 95% CI: 1.19–1.43) after con-
trolling for other occupational exposures [77]. Similar 
findings were obtained in studies conducted in the US 
trucking and non-metal mining industries [78–80]. Other 
occupations with an increased incidence of lung cancer 
include coal-mining [81], asphalt paving with coal tar 
exposure [82], chimney sweeping [83], and painting [84] 
although the risk appears to be lower than that of asbes-
tos and diesel exhaust. Other organic and metal exposures 
that have been associated with lung cancer include beryl-
lium, cadmium, chromium, silica, formaldehyde, benzo[a]
pyrene, nickel, hard metal dust, and vinyl chloride, which 
often act synergistically with tobacco smoking [84–86].
Ambient Air Pollution and Other Environmental 
Exposures
European and American studies have evaluated the 
association of ambient air pollution with lung cancer 
risk. The ESCAPE study, an analysis of multiple cohorts 
from nine European countries, found particulate mat-
ter (PM) concentration in ambient air to be significantly 
associated with lung cancer risk (hazard ratio [HR]: 1.22, 
95% CI; 1.03–1.45), particularly adenocarcinoma [87]. 
Studies in Canada [88], the Netherlands [89, 90], and 
the UK [91] also found PM with median aerodynamic 
diameter less than 2.5 μm (PM2.5), in addition to nitro-
gen oxides, nitrogen dioxide, and sulfur dioxide to be 
associated with greater risk of lung cancer. In the US, 
analysis of the Cancer Prevention Study (CPS) II cohort 
found an increase in lung cancer mortality with increas-
ing concentrations of PM2.5 in both non-smokers and 
smokers [92, 93].
Arsenic occurring naturally in drinking water and food 
has been implicated in lung cancer [94, 95]. Heck and 
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colleagues evaluated 223 lung cancer cases and found an 
OR of 2.75 (95% CI; 1.00–7.57) for small cell and squa-
mous cancers in subjects with increased toenail arsenic 
concentration [96]. Residential radon exposure is another 
known risk factor for lung cancer. An analysis of the CPS 
II cohort demonstrated a significant linear relationship 
between radon concentration and lung cancer mortality 
[97]. A Spanish case-control study found similar results, 
and also noted a strong interaction with tobacco (OR: 2.21 
95% CI: 1.33–3.69 in non-smokers vs. OR: 73 95% CI: 
20–268 in heavy smokers) [98]. 
Diet and Nutrition
Fruit and vegetable consumption have been associated 
with decreased lung cancer risk in current smokers; inges-
tion of cruciferous vegetables, in particular, has been 
inversely associated with lung cancer risk [99, 100]. An 
analysis of 264 lung cancer tissue samples showed dif-
ferentially expressed miRNAs among subjects with intake 
of quercetin-rich versus quercetin-poor fruit and vegeta-
bles [101]. Many studies have attempted to evaluate the 
effects of vitamin levels and intake on lung cancer risk. 
Dietary and supplemental calcium intake has been shown 
to be inversely associated with lung cancer risk in female 
nonsmokers (HR: 0.66, 95% CI: 0.48–0.91), current smok-
ers, particularly for lung adenocarcinoma [102, 103]. In 
addition, total iron intake was inversely associated with 
lung cancer risk in women, while total magnesium intake 
increased risk in men and current smokers; no significant 
association was found between copper, selenium, and zinc 
with lung cancer risk. Johansson and colleagues found 
elevated serum vitamin B6 and methionine levels associ-
ated with a lower risk for lung cancer in never, former, 
and current smokers in Europe [104]. Two studies showed 
a protective effect in never-smoking women with vita-
min D intake ≥ 400 IU/day and with supplemental soy 
intake [105, 106]. Conversely, the Alpha-Tocopherol, Beta-
Carotene Cancer Prevention Study, revealed a greater inci-
dence of lung cancer and overall mortality in male smok-
ers supplemented with 20mg b-carotene daily [107]. and 
prompted the US Preventive Services Task Force (USPSTF) 
to uphold their recommendation against the use of vita-
min E for the lung cancer prevention. Moreover, the USP-
STF recently concluded that there is insufficient evidence 
to recommend any vitamins, minerals, and multivitamin 
supplementation for lung cancer prevention [108]. 
Genetic Factors
Genetic factors leading to increased susceptibility to lung 
cancer have been poorly studied. First-degree relatives of 
patients with lung cancer are at increased risk, even after 
adjusting for smoking habits [109]. A meta-analysis of 28 
case-control studies and 17 observational cohort studies 
of individuals with positive family histories found a RR of 
1.84 (95% CI: 1.64–2.05) for developing lung cancer [110]. 
Additionally, genome-wide association studies have sug-
gested susceptibility loci on various chromosomes, includ-
ing 5p15.33 and 3q28, among others, but later analyses 
have not replicated these results [111, 112]. Other studies 
have identified polymorphisms in various enzymes such 
as cytochrome p450 enzymes and DNA repair genes [113], 
as well as germline mutations in the EGFR [114].
Measures of Lung Cancer Risk and Impact on 
Early Diagnosis
Except for smoking cessation, perhaps the highest reduc-
tion in lung cancer mortality rates is related to diagnosis 
at early stage followed by surgical resection. While chest 
X-rays and sputum cytology screening have not shown a 
benefit, early detection via low-dose chest tomography 
(CT) is now endorsed by the USPSTF [115]. The National 
Lung Screening Trial (NLST) compared annual screening 
by low-dose chest tomography (LDCT) with chest X-ray 
for three years at 33 US medical centers in 53,454 high-
risk subjects 55 to 74 years of age with at least 30 pack-
years of smoking and found a 20% lung cancer mortality 
reduction [116]. Ongoing European trials will provide 
additional critical information regarding the potential 
benefits of lung cancer screening [117, 118]. However, CT 
screening is associated with high rates of positive findings 
and may lead to identification of some lung cancers with 
low aggressiveness [119]. Thus, better risk stratification 
using prediction models or biomarkers of lung cancer risk, 
as well as a better understanding of the biologic charac-
teristics of aggressive cancers is required to maximize the 
benefit of screening.
Even within smokers, lung cancer risk varies consider-
ably based on factors such as age, quantity and duration 
of smoking, and environmental exposures [3]. There is 
an ongoing effort to stratify lung cancer risk to identify 
individuals best suited for lung cancer screening or refine 
eligibility for prevention trials. Several models based on 
sociodemographic characteristics, smoking, and other 
risk factors have been empirically derived using relatively 
large cohorts [120, 121]. Among these, the Bach model 
was developed using information from 18,172 subjects 
in the Carotene and Retinol Efficacy Trial, which followed 
heavy smokers and asbestos-exposed workers from 1989 
to 1996 [122]. This model was validated in the Alpha-
Tocopherol Beta-Carotene Cancer Prevention Study and 
was found to underestimate 10-year absolute lung cancer 
risk while having a discriminatory power comparable to 
breast cancer risk models [123]. Likewise, the Spitz model 
was derived and validated in a cohort of 1,851 lung cancer 
patients and 2,001 matched controls from a single tertiary 
center. Risk factors among current and former smokers, 
including exposure to environmental tobacco smoke, 
dust, fumes, chemicals, history of emphysema, and fam-
ily history of cancer, predict an increased risk for cancer 
[124]. Finally, the Liverpool Lung Project model, validated 
in multiple independent populations, is based on data 
about smoking duration, history of pneumonia or cancer, 
family history of lung cancer, and asbestos exposure to 
predict five-year lung cancer risk [125, 126].
Recent research has focused on identifying biomarkers 
of lung cancer risk, aggressive behavior among early can-
cers, and prognosis. These biomarkers may be produced by 
neoplastic cells themselves, the tumor microenvironment, 
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or the host. A variety of methods to identify biosignatures 
utilizing tissue- and biofluids-based assays have been tested 
and include genome-wide association studies (GWAS), epi-
genetics, microRNA, and proteomics [127]. Using GWAS, 
several single nucleotide polymorphisms (SNPs) have 
been identified on specific chromosomal loci – such as 
the 15q25 locus – that are associated with tobacco expo-
sure and lung cancer [128]. It remains to be seen whether 
these SNPs can be utilized in the clinical setting to assess 
lung cancer risk. Recent epigenetic studies have shown 
promise in risk stratification, with one case-control study 
using methylation of genes in sputum to identify asymp-
tomatic patients with stage I lung cancer [129]. Several 
studies have assessed circulating microRNA biomarkers. 
A 34-microRNA signature was reported to identify early-
stage NSCLC patients with 80% accuracy [130], while oth-
ers have been shown to predict recurrent disease [131] in 
plasma, surgically resected specimens, and in small biop-
sies [132]. Similarly, a 24-micro RNA signature [133], vali-
dated in a correlative study within the MILD CT-screening 
trial, was found to reduce by five-fold the false positive 
rate after low-dose CT [134]. Finally, serum proteomic sig-
natures have been integrated with CT imaging features to 
predict lung cancer diagnosis in subjects with indetermi-
nate lung nodules [135]. A seven-autoantibody signature 
has been shown to have high specificity for lung cancer-
associated antigens for early detection of lung cancer in 
a high-risk population, and also in distinguishing benign 
from malignant disease in CT-detected lung nodules; pro-
spective validation is ongoing [136]. Ajona and colleagues 
demonstrated that C4d, a degradation product of comple-
ment activation, was elevated in tumors, bronchoalveolar 
lavage fluid, and plasma samples from stage I–II lung can-
cer patients compared to controls. Additionally, C4d levels 
were associated with worse survival and increased lung 
cancer risk in screen-detected lung nodules [137]. Despite 
a substantial progress in biomarker discovery, challenges 
that remain include selection of appropriate candidate 
signatures based on tumor-specificity and high-through-
put approaches, genetic heterogeneity of tumors, and 
reproducibility in external validation studies [138, 139].
Special Populations 
Lung cancer incidence is rising in women and has in fact 
more than doubled since the mid1970s. This increase has 
been attributed to increased susceptibility in women com-
pared with men, although studies have found conflicting 
results. Data from the UK’s Health Improvement Network 
showed that female heavy smokers (>20 cigarettes daily) 
had a greater odds of developing lung cancer than men 
with comparable smoking histories, with an adjusted OR 
of 19.2 (95% CI: 17.1–21.3) in women versus 13.0 (95% 
CI: 11.7–14.5) in men [140]. However, a large prospec-
tive cohort study in the US disputed this increased sus-
ceptibility to lung cancer given equal smoking exposure 
[141, 142]. Rising rates of lung cancer in women have also 
been attributed to genetic variants, environmental expo-
sures, hormonal factors, and oncogenic viruses [141, 143]. 
The role of reproductive and hormonal factors remains 
controversial, with mixed results in studies evaluating 
associations between parity, age at menarche, and men-
opause. Although multiple case-control studies report 
increased lung cancer risk with exogenous hormone 
therapy [144–146], prospective cohort studies show equal 
lung cancer rates after adjusting for smoking rates [144, 
145, 147–150]. HPV infection has been implicated in the 
pathogenesis of lung cancer in women in Asia, but in the 
US, infection rates in tumors have been much lower [141], 
and one Finnish study of 311 women with lung cancer, 
found no evidence of increased risk for lung cancer with 
HPV 16 and 18 type-specific infections among both non-
smokers and smokers [151]. Finally, with regard to diet, a 
Japanese prospective cohort study of 126 newly diagnosed 
women with lung cancer found only a trend toward an 
association with plasma genistein, an isoflavone found in 
soy and previously shown to act as estrogen agonists and 
antagonists [152]. Although adenocarcinoma is the most 
common histologic subtype in both genders, women have 
an even higher predominance of this cell type and have a 
higher likelihood of developing adenocarcinoma in situ, a 
preinvasive lesion [141]. Additionally, several gender dif-
ferences in lung cancer mutations have been described. 
EGFR mutations are more prevalent in women, especially 
in non-smokers [153]. In particular, the L858R mutation 
has been shown to be associated with genetic polymor-
phisms related to estrogen biosynthesis and metabolism 
in never-smoking females with lung adenocarcinomas 
[153]. In one large study of the molecular epidemiology of 
lung cancer, the KRAS G12C mutation, the most common 
G>T transversion mutation in smokers, was more frequent 
in women, particularly of younger age [42]. Additionally, 
women with lung cancer have been shown in multiple 
studies to have better survival rates than men across dif-
ferent age groups, disease stage, and treatment types 
[3, 141, 154].
Approximately 10 to 20% of lung cancers occur in 
never-smokers with a much higher incidence in women 
than in men [155]. In fact, in South Asia, it is estimated 
that 83% of women with lung cancer may be never-smok-
ers [156]. It is unclear if never-smoking Asian women who 
emigrate to the US and adopt western lifestyles continue 
to have elevated risks of lung cancer, although prior litera-
ture in gastric cancer appears to suggest that risk is envi-
ronmental in nature [157]. Additional risk factors thought 
to contribute to lung cancer in never-smokers are envi-
ronmental and occupational exposures and genetic sus-
ceptibility [156]. Never-smoking women present at a more 
advanced stage, and studies from Asia have reported an 
earlier age at diagnosis compared with smokers. However, 
in the US and Europe, never-smokers and ever-smokers 
are diagnosed with lung cancer at a similar age [156]. 
With regard to histology, never-smokers have a higher 
prevalence of adenocarcinoma [156]. Additionally, while 
genomic mutations occur more frequently in current and 
former smokers compared with never-smokers, the latter 
have a higher prevalence of driver mutations including 
EGFR and ALK-EML4 [158, 159]. The EGFR mutation via 
an exon 19 deletion or exon 21 mutation is found in up 
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to 40–60% of never-smokers [42, 43, 160]. HER2 muta-
tions, a member of the EGFR family, also occurs predomi-
nantly in never-smokers [44]. In contrast, KRAS and BRAF 
mutations occur mainly in former and current smokers 
[161]. Moreover, approximately two-thirds of patients 
with ALK-EML4 rearrangements are never-smokers [45, 
46, 162]. Finally, never-smokers exhibit improved survival 
compared with smokers, even after adjusting for known 
prognostic factors [156].
Since the advent of antiretroviral therapy in the 1990s, 
cancer mortality among human immunodeficiency virus 
(HIV) patients has shifted from acquired immunodefi-
ciency syndrome (AIDS)-related malignancies to solid-
organ cancers. Lung cancer incidence is increased two- to 
four-fold in the HIV-infected population compared with 
the general population and occurs with a lower pack-
year rate of smoking [163–165]. Using the Veterans 
Affairs Central Cancer Registry, Sigel et al. found HIV to 
be an independent risk factor for the development of 
lung cancer, with an incidence rate ratio of 1.7 (95% CI: 
1.5–1.9) [166]. Multiple cohorts have shown that there is 
no difference in age, stage at presentation, or histology 
between HIV-positive and -negative patients [166, 167]. 
Lung cancer has also been found to be more aggressive 
in HIV patients, and positive HIV status has been associ-
ated with greater risk of lung cancer-specific mortality 
[168]. However, cancer-related survival has been shown 
to be better in patients with CD4 counts > 200 cells/mL 
[168–170]. Additionally, in subjects undergoing surgical 
resection, HIV patients have been found to have worse 
post-operative pulmonary and infectious complications as 
well as shorter median time to cancer progression [169].
Conclusions
This review has examined international trends in lung 
cancer epidemiology. Emerging economies and develop-
ing countries face many challenges in initiating tobacco 
cessation campaigns while also addressing environmental 
risk factors and cultural barriers. Over the past three to 
four decades, in contrast, industrialized nations have seen 
large declines in cigarette smoking and, consequently, 
lung cancer. However, despite knowledge gains in tumor 
biology that have led to targeted therapies, mortality from 
lung cancer remains high for most patients around the 
world. Future directions must include improvements in 
early detection and technological advances in genomics 
and genetics to achieve a more personalized approach to 
therapy and ultimately improve lung cancer survival.
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